Quinolinic Acid and Kynurenic Acid in the Mammalian Brain

  • R. Schwarcz
  • F. Du
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 294)


Over the last decade, the study of neuroexcitatory amino acids has become one of the most rapidly expanding areas of neuroscientific research. Interest in this class of compounds was precipitated mainly by the realization that metabolites such as glutamate and aspartate are major neurotransmitters in the central nervous system (Fonnum, 1984; Erecinska and Silver, 1990). However, it is now clear that excitatory amino acids not only play a significant role in a wide array of brain processes such as synaptic plasticity and motor control but may also, as “excitotoxins”, be causally involved in the pathogenesis of various neuro-psychiatric diseases (Cavalheiro et al., 1988). Thus, the pathological overstimulation of excitatory amino acid receptors situated in the neuronal membrane is now believed to result in neurodegeneration in cerebral hypoxia/ischemia, temporal lobe epilepsy and several other diseases including chronic neurodegenerative disorders such as Huntington’s disease (HD) (Schwarcz et al., 1984; Schwarcz and Meldrum, 1985; Rothman and Olney, 1986; Choi, 1988). Pharmacological probes have been used to subdivide the receptors which mediate excitotoxic insults. These receptor are linked to ion channels and are named after their model agonists N-methyl-D-aspartate (NMDA), kainate and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) (Watkins et al., 1990).


Temporal Lobe Epilepsy Quinolinic Acid Kynurenic Acid Excitatory Amino Acid Receptor Xanthurenic Acid 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Beal, M.F., Kowall, N.W., Swartz, K.J., Ferrante, R.J., and Martin, J.B., 1989a, Differential sparing of somatostatin-neuropeptide Y and cholinergic neurons following striatal excitotoxin lesions, Synapse 3: 38–47.PubMedCrossRefGoogle Scholar
  2. Beal, M.F., Matson, W.R., Swartz, K.J., Gamache, P.S., and Bird, E.D., 1989b, Multicomponent analysis of tryptophan and tyrosine metabolism in Huntington’s disease: evidence for reduced formation of kynurenic acid, Soc. Neurosci. Abstr., 15: 328.8.Google Scholar
  3. Cavalheiro, E.A., Lehmann, J., and Turski, L., eds., 1988, “Frontiers in Excitatory Amino Acid Research”, A. Liss, New York.Google Scholar
  4. Choi, D.W., 1988, Glutamate neurotoxicity and diseases of the nervous system, Neuron 1: 623–634.PubMedCrossRefGoogle Scholar
  5. Christensen, H.N., 1984, Organic ion transport during seven decades: the amino acids, Biochim. Biophys. Acta, 779: 255–269.PubMedGoogle Scholar
  6. Connick, J.H., Carlà, V., Moroni, F., and Stone, T.W., 1989, Increase in kynurenic acid in Huntington’s disease motor cortex, J. Neurochem., 52: 985–987.PubMedCrossRefGoogle Scholar
  7. Davies, S.W., and Roberts, P.J., 1988, Sparing of cholinergic neurons following quinolinic acid lesions of the rat striatum, Neuroscience 26: 387–393.PubMedCrossRefGoogle Scholar
  8. Du, F., Okuno, E., Whetsell, W.O. Jr., Kohler, C., and Schwarcz, R., 1990a, Distribution of quinolinic acid phosphoribosyltransferase in the human hippocampal formation and parahippocampal gyrus, J. Comp. Neurol., 295: 71–82.PubMedCrossRefGoogle Scholar
  9. Du, F., Okuno, E., Whetsell, W.O. Jr., Kohler, C., and Schwarcz, R., Immunohistochemical localization of quinolinic acid phosphoribosyltransferase in the human neostriatum, Neuroscience, in press.Google Scholar
  10. Du, F., Whetsell, W.O. Jr., Abou-Khalil, B., Blumenkopf, B., Okuno, E., and Schwarcz, R., 1990b, Immunohistochemical study of quinolinic acid catabolism in epileptic human hippocampus, Soc. Neurosci. Abstr., 16: 138.11.Google Scholar
  11. Erecinska, M., and Silver, I.A., 1990, Metabolism and role of glutamate in mammalian brain, Prog. Neurobiol., 35: 245–296.PubMedCrossRefGoogle Scholar
  12. Feldblum, S., Rougier, A., Loiseau, H., Loiseau, P., Cohadon, F., Morselli, P.L., and Lloyd, K.G., 1988, Quinolinic phosphoribosyltransferase activity is decreased in epileptic human brain tissue, Epilepsia 29: 523–529.PubMedCrossRefGoogle Scholar
  13. Fonnum, F., 1984, Glutamate: a neurotransmitter in mammalian brain, J. Neurochem., 42: 1–11.PubMedCrossRefGoogle Scholar
  14. Foster, A.C., Collins, J.F., and Schwarcz, R., 1983, On the excitotoxic properties of quinolinic acid, 2,3-piperidine dicarboxylic acids and structurally related compounds, Neuropharmacology, 22: 1331–1342.PubMedCrossRefGoogle Scholar
  15. Foster, A.C., Miller, L.P., Oldendorf, W.H., and Schwarcz, R., 1984a, Studies on the disposition of quinolinic acid after intracerebral or systemic administration in the rat, Exp. Neurol., 84: 428–440.PubMedCrossRefGoogle Scholar
  16. Foster, A.C., and Schwarcz, R., 1988, Neurotoxic effects of quinolinic acid in the central nervous system, in: “Quinolinic Acid and other Kynurenines”, Stone, T.W., ed., CRC Press, pp. 173–192.Google Scholar
  17. Foster, A.C., Vezzani, A., French, E.D., and Schwarcz, R., 1984b, Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid, Neurosci. Lett., 48: 273–278.PubMedCrossRefGoogle Scholar
  18. Foster, A.C., Whetsell, W.O. Jr., Bird, E.D., and Schwarcz, R., 1985a, Quinolinic acid phosphoribosyltransferase in human and rat brain: activity in Huntington’s disease and in quinolinate lesioned rat striaturn, Brain Res., 336: 207–214.PubMedCrossRefGoogle Scholar
  19. Foster, A.C., White, R.J., and Schwarcz, R., 1986, Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J. Neurochem., 47: 23–30.PubMedCrossRefGoogle Scholar
  20. Foster, A.C., Zinkand, W.C., and Schwarcz, R., 1985b, Quinolinic acid phosphoribosyltransferase in rat brain, J. Neurochem., 44: 446–454.PubMedCrossRefGoogle Scholar
  21. Fukui, S., Schwarcz, R., Rapoport, S.I., Takada, Y., and Smith, Q.R., Bloodbrain barrier transport of kynurenines: implications for brain synthesis and metabolism, J. Neurochem., in press.Google Scholar
  22. [Gàl, E.M., 1974, Cerebral tryptophan-2,3-dioxygenase (pyrrolase) and its induction in rat brain, J. Neurochem., 30: 607–613.CrossRefGoogle Scholar
  23. Gàl, E.M., and Sherman, A.D., 1980, L-kynurenine: its synthesis and possible regulatory function in brain, Neurochem. Res., 5: 223–239.PubMedCrossRefGoogle Scholar
  24. Ganong, A.H., Lanthorn, T.H., and Cotman, C.W., 1983, Kynurenic acid inhibits synaptic and amino acid-induced responses in the rat hippocampus and spinal cord, Brain Res., 273: 170–174.PubMedCrossRefGoogle Scholar
  25. Garthwaite, G., and Garthwaite, J., 1987, Quinolinate mimics neurotoxic actions of N-methyl-D-aspartate in rat cerebellar slices, Neurosci. Lett., 79: 35–39.PubMedCrossRefGoogle Scholar
  26. Germano, I.M., Pitts, L.H., Meldrum, B.S., Bartkowski, H.M., and Simon, R.P., 1987, Kynurenate inhibition of cell excitation decreases stroke size and deficits, Ann. Neurol., 22: 730–734.PubMedCrossRefGoogle Scholar
  27. Heyes, M.P., and Markey, S.P., 1988, Quantification of quinolinic acid in rat brain, whole blood and plasma by gas chromatography and negative chemical ionization mass spectrometry: effects of systemic L-tryptophan administration on brain and blood quinolinic acid concentrations, Anal. Biochem., 174: 349–359.PubMedCrossRefGoogle Scholar
  28. Heyes, M.P., and Nowak, T.S.J., 1990, Delayed increases in regional brain quinolinic acid follow transient ischemia in the gerbil, J. Cereb. Blood FlowMetab., 10: 660–667.CrossRefGoogle Scholar
  29. Heyes, M.P., Pappagapiou, M., Leonard, C., Markey, S.P., and Auer, R.N., 1990, Brain and plasma quinolinic acid concentrations in profound hypoglycemia, J. Neurochem., 54: 1027–1033.PubMedCrossRefGoogle Scholar
  30. Kawai, J., Okuno, E., and Kido, R., 1988, Organ distribution of rat kynureninase and changes of its activity during development, Enzyme, 39: 181–189.PubMedGoogle Scholar
  31. Kessler, M., Terramani, T., Lynch, G., and Baudry, M., 1989, A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists, J. Neurochem., 52: 1319–1328.PubMedCrossRefGoogle Scholar
  32. Kim, J.P., and Choi, D.W., 1987, Quinolinate neurotoxicity in cortical cell culture, Neuroscience, 23: 423–432.PubMedCrossRefGoogle Scholar
  33. Köhler, C., Eriksson, L.G., Okuno, E., and Schwarcz, R., 1988, Localization of quinolinic acid metabolizing enzymes in the rat brain. Immunohistochemical studies using antibodies to 3-hydroxyanthranilic acid oxygenase and quinolinic acid phosphoribosyltransferase, Neuroscience, 27: 49–76.PubMedCrossRefGoogle Scholar
  34. Köhler, C., Okuno, E., Flood, P.R., and Schwarcz, R., 1987, Quinolinic acid phosphoribosyltransferase: preferential glial localization in the rat brain visualized by immunocytochemistry, Proc. Natl. Acad. Sci. USA, 84: 3491–3495.PubMedCrossRefGoogle Scholar
  35. Lapin, I.P., 1978, Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice, J. Neural Transm., 42: 37–43.PubMedCrossRefGoogle Scholar
  36. Lapin, I.P., 1981, Kynurenines and seizures, Epilepsia, 22: 257–265.PubMedCrossRefGoogle Scholar
  37. Mangano, R.M., and Schwarcz, R., 1983, Chronic infusion of endogenous excitatory amino acids into rat striatum and hippocampus, Brain Res. Bull., 10: 47–51.PubMedCrossRefGoogle Scholar
  38. McLean, I., and Nakane, P., 1974, Periodate-lysine paraformaldehyde fixative: a new fixative for immunoelectronmicroscopy, J. Histochem. Cytochem., 22: 1077–1083.PubMedCrossRefGoogle Scholar
  39. Minatogawa, Y., Noguchi, T., and Kido, R., 1974, Kynurenine pyruvate transaminase in rat brain, J. Neurochem., 23: 271–272.PubMedCrossRefGoogle Scholar
  40. Moroni, F., Lombardi, G., Carlà, V., Lai, S., Etienne, P., and Nair, N.P.U., 1986, Increase in the content of quinolinic acid in cerebrospinal fluid and frontal cortex of patients with hepatic failure, J. Neurochem., 47: 1667–1671.PubMedCrossRefGoogle Scholar
  41. Moroni, I., Lombardi, G., Carlà, V., and Moneti, G., 1984, The excitotoxin quinolinic acid is present and unevenly distributed in the rat brain, Brain Res., 295: 352–355.PubMedCrossRefGoogle Scholar
  42. Moroni, F., Russi, P., Lombardi, G., Beni, M., and Carlà, V., 1988, Presence of kynurenic acid in the mammalian brain, J. Neurochem., 51: 177–180.PubMedCrossRefGoogle Scholar
  43. Okuno, E., Du, F., Ishikawa, T., Tsujimoto, M., Nakamura, M., Schwarcz, R., and Kido, R., 1990, Purification and characterization of kynurenine-pyruvate aminotransferase from rat kidney and brain, Brain. Res., 534: 37–44.PubMedCrossRefGoogle Scholar
  44. Okuno, E., Kohler, C., and Schwarcz, R., 1987, Rat 3-hydroxyanthranilic acid oxygenase: purification from the liver and immunocytochemical localization in the brain, J. Neurochem., 49: 771–780.PubMedCrossRefGoogle Scholar
  45. Okuno, E., Nakamura, M., and Schwarcz, R., Two kynurenine aminotransferases in rat brain, Brain Res., in press.Google Scholar
  46. Okuno, E., Schmidt, W., Parks, D.A., Nakamura, M., and Schwarcz, R., Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations, J. Neurochem., in press.Google Scholar
  47. Okuno, E., and Schwarcz, R., 1985, Purification of quinolinic acid phosphoribosyltransferase from rat liver and brain, Biochim. Biophys. Acta, 841: 112–119.PubMedCrossRefGoogle Scholar
  48. Okuno, E., White, R.J., and Schwarcz, R., 1988, Quinolinic acid phosphoribosyltransferase: purification and partial characterization from human liver and brain, J. Biochem., 103: 1054–1059.PubMedGoogle Scholar
  49. Perkins, M.N., and Stone, T.W., 1982, An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid, Brain Res., 247: 184–187.PubMedCrossRefGoogle Scholar
  50. Reynolds, G.P., Pearson, S.J., Halket, J., and Sandler, M., 1988, Brain quinolinic acid in Huntington’s disease, J. Neurochem., 50: 1959–1960.PubMedCrossRefGoogle Scholar
  51. Rothman, S.M., and Olney, J.W., 1986, Glutamate and the pathophysiology of hypoxic-ischemic brain damage, Ann. Neurol., 19: 105–111.PubMedCrossRefGoogle Scholar
  52. Schwarcz, R., Foster, A.C., French, E.D., Whetsell, W.O. Jr., and Kohler, C., 1984, Excitotoxic models for neurodegenerative disorders, Life Sci., 35: 19–32.PubMedCrossRefGoogle Scholar
  53. Schwarcz, R., and Kohler, C., 1983, Differential vulnerability of central neurons to quinolinic acid, Neurosci. Lett., 38: 85–90.PubMedCrossRefGoogle Scholar
  54. Schwarcz, R., and Meldrum, B., 1985, Excitatory amino acid antagonists provide a novel therapeutic approach to neurological disorders, Lancet, 2: 140–143.PubMedCrossRefGoogle Scholar
  55. Schwarcz, R., Okuno, E., Speciale, C., Whetsell, Jr. W.O., and Kohler, C., 1987, Neuronal degeneration in animals and man: the quinolinic acid connection. in: “Neurotoxins and their Pharmacological Implications”, Jenner, P.G., ed., Raven, pp. 19–32.Google Scholar
  56. Schwarcz, R., Okuno, E., and White, R.J., 1989, Basal ganglia lesions in the rat: effects on quinolinic acid metabolism, Brain Res., 490: 103–109.PubMedCrossRefGoogle Scholar
  57. Schwarcz, R., Okuno, E., White, R.J., Bird, E.D., and Whetsell, W.O. Jr., 1988a, 3-Hydroxyanthranilic acid oxygenase activity is increased in the brains of Huntington disease victims, Proc. Natl. Acad. Sci. USA, 85: 4079–4081.PubMedCrossRefGoogle Scholar
  58. Schwarcz, R., Tamminga, C., Kurlan, R., and Shoulson, I., 1988b, Cerebrospinal fluid levels of quinolinic acid in Huntington’s disease and schizophrenia, Ann. Neurol., 24: 580–582.PubMedCrossRefGoogle Scholar
  59. Schwarcz, R., Turski, W.a., and Gramsbergen, J.B.P., 1988c, Enhanced kynurenic acid synthesis in cortical and hippocampal slices from aged rats, Soc. Neurosci. Abstr., 14: 99.7.Google Scholar
  60. Schwarcz, R., Whetsell, W.O. Jr., and Mangano, R.M., 1983, Quinolinic acid: an endogenous metabolite that causes axon-sparing lesions in rat brain, Science, 219: 316–318.PubMedCrossRefGoogle Scholar
  61. Shibata, K., 1988, Fluorimetric micro-determination of kynurenic acid, an endogenous blocker of neurotoxicity, by high-performance liquid chromatography, J. Chromatogr., 430: 376–380.PubMedCrossRefGoogle Scholar
  62. Simon, R.P., Young, R.S.K., Stont, S., and Cheng, J., 1986, Inhibition of excitatory neurotransmission with kynurenate reduces brain edema in neonatal anoxia, Neurosci. Lett., 71: 361–364.PubMedCrossRefGoogle Scholar
  63. Speciale, C., Hares, K., Schwarcz, R., and Brookes, N., 1989a, High-affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes, J. Neurosci., 9: 2066–2072.PubMedGoogle Scholar
  64. Speciale, C., Okuno, E., and Schwarcz, R., 1987, Increased quinolinic acid metabolism following neuronal degeneration in the rat hippocampus, Brain Res., 436: 18–24.PubMedCrossRefGoogle Scholar
  65. Speciale, C., and Schwarcz, R., 1990, Uptake of kynurenine into rat brain slices, J. Neurochem., 54: 156–163.PubMedCrossRefGoogle Scholar
  66. Speciale, C., Ungerstedt, U., and Schwarcz, R., 1989b, Production of extracellular quinolinic acid in the striatum studied by microdialysis in unanesthetized rats, Neurosci. Lett., 104: 345–350.PubMedCrossRefGoogle Scholar
  67. Speciale, C., Wu, H.-Q., Gramsbergen, J.B.P., Turski, W.A., Ungerstedt, U., and Schwarcz, R., 1990, Determination of extracellular kynurenic acid in the striatum of unanesthetized rats: effect of aminooxyacetic acid, Neurosci. Lett., 116: 198–203.PubMedCrossRefGoogle Scholar
  68. Swartz, K.J., During, M.J., Freese, A., and Beal, M.F., 1990, Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors, J. Neurosci., 10: 2965–2973.PubMedGoogle Scholar
  69. Takahashi, H., Kaihara, M., and Price, J.M., 1956, The conversion of kynurenic acid to quinaldic acid by humans and rats, J. Biol. Chem., 223: 705–708.PubMedGoogle Scholar
  70. Turski, W.A., Gramsbergen, J.B.P., Traitler, H., and Schwarcz, R., 1989, Rat brain slices produce and liberate kynurenic acid upon exposure to L-kynurenine, J. Neurochem., 52: 1629–1636.PubMedCrossRefGoogle Scholar
  71. Turski, W.A., Nakamura, M., Todd, W.P., Carpenter, B.K., whetsell, W.O. Jr., and Schwarcz, R., 1988, Identification and quantification of kynurenic acid in human brain tissue, Brain Res., 454: 164–169.PubMedCrossRefGoogle Scholar
  72. Turski, W.A., and Schwarcz, R., 1988, On the disposition of intrahippocampally injected kynurenic acid in the rat, Exp. Brain Res., 71: 563–567.PubMedCrossRefGoogle Scholar
  73. Watkins, J.C., Krogsgaard-Larsen, P., and Honoré, 1990, Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists, Trends Pharmacol. Sci., 11: 25–33.PubMedCrossRefGoogle Scholar
  74. Whetsell, W.O. Jr., and Schwarcz, R., 1983, The organotypic tissue culture model of corticostriatal system used for examining amino acid neurotoxicity and its antagonism: studies of kainic acid, quinolinic acid and (−) 2-amino-7-phosphonoheptanoic acid, J. Neural Transm., Suppl., 19: 53–63.Google Scholar
  75. Wolfensberger, M., Amsler, U., Cuénod, M., Foster, A.C., Whetsell, W.O. Jr., and Schwarcz, R., 1983, Identification of quinolinic acid in rat and human brain tissues, Neurosci. Lett., 41: 247–252.PubMedCrossRefGoogle Scholar
  76. Wu, H.-Q., and Schwarcz, R., 1990, Dual regulation of kynurenic acid production in rat hippocampus in vivo. Soc. Neurosci. Abstr., 16: 200.11.Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • R. Schwarcz
    • 1
  • F. Du
    • 1
  1. 1.Maryland Psychiatric Research CenterBaltimoreUSA

Personalised recommendations